Navigation Links
Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions
Date:1/25/2012

FLORHAM PARK, N.J., Jan. 25, 2012 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced results from two studies published online today in the journal Therapeutics and Clinical Risk Management: the first study, a randomized, double-blind, placebo-controlled phase III trial, showed that children ages 3-16 with problem drooling due to neurologic conditions demonstrated a significantly better response to CUVPOSA® (glycopyrrolate) oral solution than to placebo.(1) The second study, a multicenter, open-label trial, evaluated the safety and efficacy of CUVPOSA® for over 24 weeks.(2)  The majority of patients in this study were between the ages of 3-16 with moderate-to-severe drooling.  CUVPOSA® oral solution is the first and only U.S. Food and Drug Administration-approved treatment to reduce chronic severe drooling in patients ages 3-16 with neurologic conditions associated with problem drooling, such as cerebral palsy.  

"Chronic severe drooling is a health issue for children with neurologic disorders," said lead study investigator Robert S. Zeller, MD, director, Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital, Houston, Texas. "These studies reinforce the efficacy and safety, respectively, of CUVPOSA®." 

After eight weeks in the first study of 38 patients [CUVPOSA® (n=20), placebo (n=18)], 14 of 19 patients (73.7 percent) in the CUVPOSA® group and three of 17 (17.6 percent) in the placebo group exhibited at least a 3-point improvement on the modified Teacher's Drooling Scale (mTDS) (P=0.0011).  Two of the 38 patients were older than 16 and, as such, were excluded from the results.  A beneficial effect of CUVPOSA® was observed as early as two weeks after treatment initiation (52.6 percent; P=0.0007), with the proportion of responders increasing continuously through week 8.  M
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... YORK , Sept. 2, 2014 Reportlinker.com ... in its catalogue: Asia - Pacific ... http://www.reportlinker.com/p02353212/Asia---Pacific-Minimally-Invasive-Surgery-Spinal-Device-Market.html The growth rate of ... spinal device market will remain at double-digit levels throughout ... surgeries as the future of this field. The ...
(Date:9/2/2014)... -- Perrigo Company plc, a public limited company incorporated under ... Company "), today announced that it is offering to exchange ... Senior Notes due 2016 (the " 2016 Exchange Notes "), ... " 2018 Exchange Notes "), $800,000,000 of its new 4.00% ... and $400,00,000 of its new 5.30% Senior Notes due 2043 ...
(Date:9/2/2014)... , Sept. 2, 2014  Ameritox SM , ... "A Deadly Trend: Prescription Drugs to Heroin," a research ... to heroin abuse, and examines deadly trends that have ... found here . The report ... of patients prescribed opioids. It examines five trends that ...
Breaking Medicine Technology:Asia - Pacific Minimally Invasive Surgery Spinal Device Market 2Asia - Pacific Minimally Invasive Surgery Spinal Device Market 3Asia - Pacific Minimally Invasive Surgery Spinal Device Market 4Asia - Pacific Minimally Invasive Surgery Spinal Device Market 5Asia - Pacific Minimally Invasive Surgery Spinal Device Market 6Asia - Pacific Minimally Invasive Surgery Spinal Device Market 7Asia - Pacific Minimally Invasive Surgery Spinal Device Market 8Asia - Pacific Minimally Invasive Surgery Spinal Device Market 9Asia - Pacific Minimally Invasive Surgery Spinal Device Market 10Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2
... Inc., a pharmaceutical company advancing orally-available antiviral therapeutics to ... President and Chief Executive Officer, will present at the ... 2011 at 3:00 p.m. ET at the Hilton New ... Mr. Moch will give an update on the company,s ...
... Codexis, Inc. (Nasdaq: CDXS ) today announced ... Officer and Senior Vice President, Process Development and Manufacturing, a ... Ph.D., President and Chief Executive Officer. Dr. ... DuPont. He served as Vice President, Research and Development for ...
Cached Medicine Technology:Chimerix to Present at the Citi 2011 Global Health Care Conference 2Chimerix to Present at the Citi 2011 Global Health Care Conference 3Codexis Names David Anton CTO & SVP, Process Development & Manufacturing 2
(Date:9/2/2014)... On August 30, 2014, Harper’s Bazaar ... You Should Wash Your Face .” According to ... population breathes air considered polluted by the World Health ... the skin’s pores destroying its natural oils. These oils ... that may cause cell damage, redness, aging skin ...
(Date:9/2/2014)... patients treated with lumpectomy followed by radiation therapy ... mastectomy, according to a large study conducted by ... and the Cancer Prevention Institute of California. , ... with the disease is the first to directly ... surgical interventions: bilateral mastectomy (the removal of both ...
(Date:9/2/2014)... 2, 2014 In a large population-based study ... that mild cognitive impairment (MCI) occurred twice more ... 2. Interestingly, this strong association was only observed ... participants (66-80 years) the association vanished. This study ... Disease . , The concept of MCI describes ...
(Date:9/2/2014)... within a few days of discharge do so principally because ... in other parts of the health care system, according to ... Annals of Emergency Medicine ( "Return Visits to the ... asked why they did not follow up as an outpatient, ... wait until their scheduled appointment or being instructed to return ...
(Date:9/2/2014)... 02, 2014 The Dream2Walk Foundation along with ... Sept. 14th, 2014 during Spinal Cord Injury Awareness Month featuring ... England, and Chuck Ligon. Linear Automotive will be there hosting ... , Doors open at 2pm. The car show is Pre ... free pass to the concert. There will be trophies for ...
Breaking Medicine News(10 mins):Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
... Is it safe to wait to make a,decision about ... for all the doctor appointments and test results? Or ... Reassuring research,says that men can take the time they ... of Harvard Men,s Health Watch., One study evaluated ...
... and caregivers offers tips to families, friends, caregivers ... ... CHICAGO, Feb. 4 What do you say, what can you ... from a serious,disease? To kick-off National Patient Recognition Week, a week-long,observance ...
... More than half a million women around the world, ... natural family planning methods developed by Georgetown University Medical ... and thousands of others use CycleBeads a visual aid ... fertility to plan or prevent pregnancy. , Now ...
... York Methodist Hospital today announced the start of the ... multi-center clinical trial to explore an investigational treatment that ... suffering with advanced widespread emphysema. The study focuses on ... in the lung for trapped air to escape and ...
... the Stowers Institutes Trainor Lab has demonstrated that it can ... a gene implicated in the abnormality or by inhibiting its ... the Web site of the journal Nature Medicine yesterday, is ... cause of TCS. , The team evaluated how a ...
... Provide Insight ... 50+-year Relationships, MCLEAN, Va., Feb. 4 Sunrise Senior Living,(NYSE: ... services with,more than 450 communities worldwide, shared the results of a ... spent more than,five decades of special Valentine,s Days together., Sunrise ...
Cached Medicine News:Health News:Men Can Take Their Time to Decide on Prostate Cancer Treatment, Reports the Harvard Men's Health Watch 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 3Health News:CycleBeads help women manage their fertility 2Health News:New York Methodist Hospital to study airway bypass treatment for emphysema 2Health News:Trainor Lab prevents rare birth defect by inactivating p53 gene 2Health News:Secrets to Long-Lasting Marriages Revealed in Senior Survey 2Health News:Secrets to Long-Lasting Marriages Revealed in Senior Survey 3
... 3 year warranty Set one of ... for B.I.O. exam!, One touch auto return ... in 4 colors , Solid-State push button ... holder and transformer. , Electro-Magnetic counter-balanced slit ...
3.5v Standard Ophthalmoscope Set with Convertible Handle and Soft Case. Our Standard Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
High-quality eyecare from the preferred name in diagnostic instruments....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: